2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
August 19th 2020
Anna C. Pavlick, DO, discusses the longer follow-up of the phase 2 EMPOWER-CSCC-1 study with cemiplimab in cutaneous squamous cell carcinoma.
August 13th 2020
Anna C. Pavlick, DO, discusses common and uncommon adverse effects with cemiplimab in patients with cutaneous squamous cell carcinoma.
May 1st 2020
Anna C. Pavlick, DO, discusses updated results from the COLUMBUS trial in metastatic melanoma.
March 31st 2020
Anna C. Pavlick, DO, discusses sequencing challenges faced in the treatment of patients with BRAF-mutant melanoma.
January 27th 2020
Anna C. Pavlick, DO, discusses the importance of immunotherapy for patients with metastatic melanoma.
July 27th 2017
Anna C. Pavlick, DO, associate professor of hematology and medical oncology and medical director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the need for adjuvant immunotherapy in patients with high-risk melanoma.
December 20th 2016
Anna C. Pavlick, DO, medical oncologist, NYU Langone School of Medicine, discusses ongoing clinical trials exploring treatment with immunotherapy in patients with basal cell carcinoma as well as squamous cell carcinoma.
May 28th 2014
Anna C. Pavlick, DO, associate professor, Hematology and Medical Oncology, medical director, Clinical Trials Office, Perlmutter Cancer Center at NYU Langone, discusses a phase II trial exploring low-dose cyclophosphamide and ipilimumab in metastatic melanoma.